Proven effectiveness in multiple RCTs with over 7.000 patients
10 year R&D experience, 20+ CE & FDA compliant products
Indication/Pipeline: CNS, immunology, oncology
Feel free to write us an email.
GAIA is a global pioneer in digital therapy, launching its first programme successfully in 2001.
Our mission: Developing therapeutic software that offers physicians, therapists, payers and patients the same effect sizes, similar safety profiles, and equal levels of convenience as found in well-developed pharmaceutical solutions.
Our multidisciplinary expert teams cover all competencies required to develop, launch and maintain top-of-class products for major markets: Experienced physicians and psychotherapists, clinical scientists experienced in orchestrating Phase II & III trials, IT and software engineers, regulatory affairs experts as well as market access specialists.
One of our most researched products is deprexis®, the online programme for the treatment of depression. deprexis® has been shown to effectively reduce symptoms of depression in 9 randomized controlled trials (RCTs) as well as in real-life clinical settings, with effect sizes similar to those of antidepressants. Deprexis is licensed to Servier for the German market. For more information, please visit deprexis.com or deprexis24.de.
Our current R&D pipeline covers a range of phase II and phase III next generation digital therapy solution, for conditions such as borderline personality disorder (priovi®), generalized anxiety disorder / panic disorder / social phobia (velibra®), fatigue in multiple sclerosis (elevida®), epilepsy, or compliance support (covivio®), among others. For more detailed information regarding our pipeline or requests for research and development partnerships, please contact us directly via mail or phone.
Our expert system technology platform broca® forms the backbone of more than 70 products developed to date. Started as a joint venture with the Airbus group, broca® has set healthcare industry benchmarks for individualized web based solutions. Our programmes simulate 1:1 coaching, training or therapy sessions, in which a virtual expert and a user interact intensively to achieve a particular goal. Similar to a chess computer, broca® facilitates rapid learning, thought process change and deep skill acquisition in a dynamic and individual flow. The programme engages users continuously in interactive exercises and guides them, step-by-step, towards specific goals and therapeutic targets.
The latest version of our broca® 4 software affords the flexibility to run our highly individualised programs on nearly all web-compatible devices including virtual reality applications. Consistent with a “quantified-self” approach, we can now capture and visually display a host of performance parameters, assessed either directly within the systems or via interfaces. Our broca® 4 software enables us to integrate such parameters in our individualised, dialogue-based programs, allowing us to produce even more targeted and custom-tailored interventions. The new platform offers many options for health care professionals wishing to monitor and support their patients’ programme use.
GAIA has developed and implemented digital therapy projects with international partners, such as pharmaceutical companies and healthcare providers. Among others these are: Abbvie, Airbus, AOK, B. Braun, Desitin, DAK, Ferring, J&J, E. Lilly, Lundbeck, Merck, Merz, Pfizer, Servier etc.